Korte SM, Straub RH. Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms. Rheumatology (Oxford). 2019;58(Suppl 5):v35–50.
Article CAS PubMed Google Scholar
Chavarría C, Casanova MJ, Chaparro M, et al. Prevalence and factors associated with fatigue in patients with inflammatory bowel disease: a multicentre study. J Crohns Colitis. 2019;13(8):996–1002.
Graff LA, Walker JR, Russell AS, et al. Fatigue and quality of sleep in patients with immune-mediated inflammatory disease. J Rheumatol Suppl. 2011;88:36–42.
Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5):v29–34.
Katz P. Causes and consequences of fatigue in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(3):269–76.
Grimstad T, Norheim KB. Fatigue in inflammatory bowel disease. Tidsskr Nor Laegeforen. 2016;136(20):1721–4.
Swain MG. Fatigue in chronic disease. Clin Sci (Lond). 2000;99(1):1–8.
Article CAS PubMed Google Scholar
Davis JM 3rd, Myasoedova E, Gunderson TM, et al. Multimorbidity and fatigue in rheumatoid arthritis: a cross-sectional study of a population-based cohort. Rheumatol Ther. 2020;7(4):979–91.
Article PubMed PubMed Central Google Scholar
Minnock P, Veale DJ, Bresnihan B, et al. Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis. Clin Rheumatol. 2015;34(11):1857–65.
Article PubMed PubMed Central Google Scholar
Haugeberg G, Hoff M, Kavanaugh A, et al. Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. Arthritis Res Ther. 2020;22(1):198.
Article PubMed PubMed Central Google Scholar
Almeida C, Choy EH, Hewlett S, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6): CD008334.
PubMed PubMed Central Google Scholar
Yip RML, Yim CW. Role of interleukin 6 inhibitors in the management of rheumatoid arthritis. J Clin Rheumatol. 2021;27(8):e516–24.
Skoie IM, Dalen I, Omdal R. Effect of biological treatment on fatigue in psoriasis: a systematic review and meta-analysis. Am J Clin Dermatol. 2019;20(4):493–502.
Shim J, Dean LE, Karabayas M, et al. Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. Rheumatology (Oxford). 2020;59(11):3408–14.
Article CAS PubMed Google Scholar
Kvien TK, Conaghan PG, Gossec L, et al. secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis: long-term results of two phase III randomized controlled trials. Arthritis Care Res (Hoboken). 2022;74(5):759–67.
Reilly E, McGrogan A, Sengupta R. Evaluating patient-reported fatigue and serum biomarkers in axial spondyloarthritis. Rheumatology (Oxford). 2020;59(10):3111–3.
Laganà B, Vinciguerra M, D’Amelio R. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. Clin Drug Investig. 2009;29(3):185–202.
Druce KL, Bhattacharya Y, Jones GT, et al. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(10):1786–90.
Article CAS PubMed Google Scholar
Wang F, Lin X, Zhao Q, et al. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol. 2015;71(8):911–9.
Article CAS PubMed Google Scholar
Vogelaar L, van’t Spijker A, van Tilburg AJ, et al. Determinants of fatigue in Crohn’s disease patients. Eur J Gastroenterol Hepatol. 2013;25(2):246–51.
van Lint JA, Jessurun NT, Hebing RCF, et al. Patient-reported burden of adverse drug reactions attributed to biologics used for immune-mediated inflammatory diseases. Drug Saf. 2020;43(9):917–25.
Kosse LJ, Jessurun N, Hebing RCF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology (Oxford). 2020;59(6):1253–61.
Van Lint J, Bakker T, Ubbink J, et al. OP0208: patients report fatigue as an adverse drug reaction of biologics. Ann Rheum Dis. 2020;79(Suppl 1):129–30.
Remicade® Product Information: European Medicines Agency [updated 12 Nov 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf.
Enbrel® Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf.
Humira® Product Information: European Medicines Agency [updated 29 Jan 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf.
Cimzia® Product Information: European Medicines Agency [updated 7 Apr 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf.
Simponi® Product Information: European Medicines Agency [updated 11 Nov 2020; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf.
Orencia® Product Information: European Medicines Agency [updated 6 Oct 2020; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/orencia-epar-product-information_en.pdf.
Kyntheum® Product Information: European Medicines Agency [updated 27 Jul 2020; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf.
Ilaris® Product Information: European Medicines Agency [updated 25 Feb 2020; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf.
Mabthera® Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf.
Cosentyx® Product Information: European Medicines Agency [updated 25 Mar 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf.
Stelara® Product Information: European Medicines Agency [updated 12 Mar 2021; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.
Entyvio® Product Information: European Medicines Agency [updated 30 Nov 2020; cited 21 Apr 2021]. https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf.
Remicade® Product Label: US FDA [updated 10 May 2021; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf.
Cimzia® Product Label: US FDA [updated 22 Dec 2022; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125160s305lbl.pdf.
Siliq® Product Label: US FDA [updated 15 Feb 2017; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
Stelara® Product Label: US FDA [updated 29 Jul 2022; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761044s010lbl.pdf.
Truxima® Product Label: US FDA [updated 04 Feb 2022; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761088s018lbl.pdf.
Entyvio® Product Label: US FDA [updated 17 Jun 2022; cited 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125476Orig1s046lbl.pdf.
MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities: Northrop Grumman Corporation. http://www.meddra.org/.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
Article CAS PubMed Google Scholar
RoActemra® Product Information: European Medicines Agency [updated 14 Sep 2020; cited 11 May 2021]. https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf.
Ćalasan MB, van den Bosch OF, Creemers MC, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther. 2013;15(6):R217.
Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383–9.
Article CAS PubMed Google Scholar
Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–15.
Article PubMed PubMed Central Google Scholar
Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–9.
Article CAS PubMed Google Scholar
Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219–24.
Article PubMed PubMed Central Google Scholar
Bots SJ, Parker CE, Brandse JF, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35(6):715–33.
Article CAS PubMed PubMed Central Google Scholar
Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
Article CAS PubMed PubMed Central Google Scholar
Skoie IM, Dalen I, Ternowitz T, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol. 2017;177(2):505–12.
Article CAS PubMed Google Scholar
Ibn Yacoub Y, Amine B, Laatiris A, et al. Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int. 2012;32(7):1901–7.
Conley S, Proctor DD, Jeon S, et al. Symptom clusters in adults with inflammatory bowel disease. Res Nurs Health. 2017;40(5):424–34.
留言 (0)